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Summary
In the era of antiretroviral therapy (ART) as prevention for
transmission of HIV as well as treatment for HIV-posit-
ive individuals irrespective of CD4 cell counts, the import-
ance of adherence has grown. Although adherence is not
the only determinant of treatment success, it is one of the
only modifiable risk factors. Treatment failure reduces fu-
ture treatment options and therefore long-term clinical suc-
cess as well as increases the possibility of developing drug
resistant mutations. Drug-resistant strains of HIV can then
be transmitted to uninfected or drug-naïve individuals lim-
iting their future treatment options, making adherence an
important public-health topic, especially in resource-lim-
ited settings.
Adherence should be monitored as a part of routine clinical
care; however, no gold standard for assessment of adheren-
ce exists. For use in daily clinical practice, self-report is the
most likely candidate for widespread use due to its many
advantages over other measurement methods, such as low
cost and ease of administration. Asking individuals about
their adherence behaviour has been shown to yield valid
and predictive data – well beyond the mere flip of a coin.
However, there is still work to be done. This article reviews
the literature and evidence on self-reported adherence,
identifies gaps in adherence research, and makes recom-
mendations for clinicians on how to best utilise self-repor-
ted adherence data to support patients in daily clinical prac-
tice.
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Adherence – definitions and
terminology
The World Health Organization (WHO) defines adherence
as “the extent to which a person’s behaviour – taking med-
ications, following diet and/or executing lifestyle changes
– corresponds with agreed recommendations from a health
care provider”. It is estimated that adherence to long-term
therapy for chronic illness in developed countries averages
50% and is even lower in developing countries [1]. Poor
adherence leads to poor patient outcomes, increased health
care costs, decreases patient safety, and diminishes the ef-
fectiveness of improvements in and access to medications.
In the context of HIV, adherence to antiretroviral therapy
(ART) can be defined as the “ability of the person living
with HIV/AIDS to be involved in choosing, starting, man-
aging, and maintaining a given therapeutic medication re-
gimen to control HIV replication and to improve immune
function” [2]. This definition of adherence – with an em-
phasis on the patient’s role in choosing both when to start
ART and which ART to take – highlights the movement to-
ward a ‘new’ paradigm of provider-patient interaction for
HIV care as suggested by Noring and colleagues [3]. A key
element of the recommendations from this working group
was the idea that the term ‘adherence’ should be replaced
with ‘treatment maintenance’ as it better reflects the col-
laborative relationship between a patient as proactive par-
ticipant and a provider as professional guide. In support
of this are the European AIDS Clinical Society (EACS)
guidelines which emphasise patient readiness to start ART
as a key to adherence and successful treatment [4].
Why measure adherence?
Regardless of how one defines and names this concept, the
importance of adherence to ART has increased as HIV has
become a chronic illness and treatment of HIV requires
life-long therapy once initiated. Although adherence is not
the only determinant of treatment success, non-adherence
is the most critical and one of the only modifiable risk
factors leading to a chain of negative clinical outcomes,
resulting in both personal and public-health implications.
Treatment failure
The initial goal of ART is to not only attain but maintain an
undetectable viral load. Early reports in individuals on non-
boosted protease inhibitors (PIs) estimated that they must
take 95% of their medication to remain virally suppressed
[12]. Several studies were done to explore whether the 95%
rule applied to other drug classes and found non-nucle-
oside reverse transcriptase inhibitors (NNRTI) and boos-
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ted PI regimens to be more ‘forgiving’ – able to achieve
and maintain viral suppression despite imperfect medica-
tion adherence [13–16]. Recent evidence looking at an in-
tegrase inhibitor (raltegravir) found that the risk of virolo-
gic failure was 50% after treatment interruptions of 7 days
compared to a 15–day interruption on an NNRTI [17]. The
majority of patients on potent regimens are able to main-
tain viral suppression at adherence rates lower than 95%
[18–21].
Resistance
Virologic failure not only reduces future treatment options
and therefore long-term clinical success but also increases
the possibility of developing drug resistant mutations [6,
7, 23]. Studies of the relationship between adherence and
resistance in HIV indicate that the relationship is more
complicated than originally thought, with each drug class
having a unique adherence-resistance relationship [26–29].
Boosted PI regimens – PIs taken with ritonavir (or cobi-
cistat) – allow for more potent viral suppression than un-
boosted PI regimens [30] and have a longer half-life so PI
concentrations remain at subinhibitory concentrations for
only a brief time during periods of non-adherence [31]. In
addition, this allows for a once daily formulation which
for some patients may have a positive impact on adherence
[32]. Resistance to PIs usually requires multiple mutations;
therefore high level resistance requires both ongoing viral
replication and sufficient drug exposure to create a select-
ive advantage for drug-resistant virus [31].
For NNRTI regimens, resistance is associated with inter-
ruptions in therapy [33] and develops at a lower level of
adherence than PI resistance [34]. Unlike most PI drugs,
resistance to the NNRTIs nevirapine and efavirenz requires
only a single mutation [35]. However, most NNRTIs have
longer half-lives requiring more than one missed dose for
the virus to replicate at subinhibitory plasma drug concen-
trations [36]. The clinical implications of NNRTI resistance
are considerable since NNRTI resistance almost univer-
sally confers to cross-resistance to first generation NNRTIs
[37]. In case of virological failure, the accumulation of
NRTI mutation is higher for patients failing a NNRTI re-
gimen compared to patients failing a boosted PI regimen
[38]. The mechanism behind the protective effect of PIs on
NRTIs remains unclear but has been confirmed in clinical
trials and cohorts.
AIDS-defining illness and mortality
Several studies have shown non-adherence to be associated
with mortality [39–42] and progression to AIDS [43]. A
meta-analysis of the association between adherence and
mortality found a pooled odds ratio of death in the subset of
HIV studies of 0.53 (95% CI: 0.41 –0.69) in adherent pa-
tients compared to non-adherent patients [44].
Public health implications of non-adherence to
antiretroviral drugs
The importance of adherence in the life of an HIV-infected
person on ART is undisputed. However, the adherence pat-
terns of individuals can also have public health implica-
tions. In those already infected with HIV, it is now known
that ART reduces the viral load and therefore infectious-
ness, limiting the risk of onward transmission [45–48]. The
test and treat policy – universal HIV testing to enhance the
identification of all HIV-positive individuals followed by
immediate treatment irrespective of their CD4 cell counts –
has been postulated as a potential tool capable of reducing
HIV incidence at a population level [49, 50].
Pre-exposure prophylaxis (PrEP), the use of antiretroviral
agents by HIV-uninfected persons before potential sexual
exposure to HIV-infected partners, is a new approach to
HIV prevention and has been approved by the FDA in 2013
[51]. Several double-blind randomised clinical trials have
studied the efficacy and tolerance of PrEP to prevent HIV
acquisition in high risk groups with varying results with
regards to efficacy [52–55]. This large range of efficacy
(0–75%) has been mostly linked to adherence to PrEP. Not
surprisingly the adherence (and efficacy) was highest in
the study that randomised individuals who had sex with an
HIV infected stable partner compared to studies where in-
dividuals had sexual partners of unknown HIV status. The
potential to develop resistance from PrEP can jeopardise
the therapeutic use of these drugs in the subsequent treat-
ment of the individual and for the community at large if
resistance to the agents spreads more broadly [56, 57]. The
low adherence levels reported in some of these studies
[54] lend credence to these concerns especially in settings
where adherence, viral load, and resistance are not being
monitored.
How should adherence be measured?
The importance of adherence as a predictor or determinant
of the success of treatment has been clearly documented
above, and as such, it would seem clear that the adherence
of a patient should be closely monitored. In addition, ad-
herence is a dynamic process and has been shown to vary
over time [58–63] and therefore should be measured regu-
larly as part of routine clinical care. However, there is no
gold standard for the assessment of adherence nor is there
a single optimal tool that enhances adherence to HIV treat-
ment regimens [64].
There are five main methods for adherence measurement:
self-report, medication event monitoring system (MEMS),
pill count, pharmacy refill, and therapeutic drug monitoring
(TDM). Each method has its own strengths and weaknesses
and therefore the choice of measurement method often de-
pends on the purpose and intended use of the measurement.
Using a combination of methods to measure adherence is
likely to provide the most accurate results. Several articles
have provided a good overview of measurement methods
[65, 66].
Asking about adherence
For the purpose of this article, we will focus on self-repor-
ted adherence. Self-report is by far the simplest and most
convenient method of measuring adherence. The main ad-
vantages are its low cost, low staff and respondent burden,
and extreme flexibility [65]. Self-report can measure all
four dimensions of adherence behaviour – taking adheren-
ce (the extent to which a patient is taking the prescribed
medication), timing adherence (the extent to which a pa-
tient is adhering to the prescribed schedule for drug intake),
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drug holidays (missing several doses of medication in a
row), and food restrictions (the extent a patient is adhering
to drug intake in relation to food restrictions) [1]. For use in
daily clinical practice and management of a patient, self-re-
port comes out as the most likely candidate for widespread
use due to its many advantages over other measurement
methods especially when considering resource-limited set-
tings.
However, self-report is subject to overreporting [67]. While
patients’ reporting of non-adherence has been found to be
credible [68, 69], their estimate of adherence is often inac-
curate [70, 71] overestimating adherence by 10–20% com-
pared to MEMS [72, 73] and 5–10% compared to TDM
[69]. A recent study in PrEP in high-risk African women
found self-reported adherence to be unreliable with 95% of
women reporting taking the drugs on a regular basis where-
as only 22% showed evidence of taking the drug on study
visits according to TDM [54].
Belli and colleagues suggested the cognitive processes re-
sponsible for this overreporting are intentional deception
and misremembering [74]. Intentional deception happens
as a result of social-desirability bias; the tendency of pa-
tient’s to answer questions in a manner that will be viewed
favourably by others. Respondents may alter their re-
sponses if they believe answers will trigger either pleasant
or unpleasant reactions. Most of the overreporting of ad-
herence, however, is thought to be due to misremembering
[75] which presents a tougher challenge to overcome.
When asking about mundane behaviour carried out on a
routine basis, it is believed that patients are unable to separ-
ate action from intention. So when they report having taken
their medication, they may be misremembering their inten-
tion to take the medication as the actual act of taking the
medication.
There exist many different validated self-report instru-
ments for measuring adherence complicating the compar-
ability and interpretability of study findings. Adherence
questions range from global estimates of how much medic-
ation was taken using estimation recall to specific inquiries
into the exact number of missed doses utilising count-based
recall. The methods for administering questionnaires also
differ, such as structured interviews and paper or computer
self-assessments. Nevertheless, two systematic reviews in-
cluding a large number of observational studies (mostly
count-based) found a robust association between self-re-
ported adherence and viral load over varying measures and
recall periods [76] and indicated that self-reported adher-
ence measures can distinguish between clinically meaning-
ful patterns of medication-taking behaviour [77]. Simoni
and colleagues found that self-reported adherence was sig-
nificantly correlated with viral load in 84% of comparisons
[76]. Nieuwkerk and Oort compiled 65 studies of self-re-
ported adherence to estimate a pooled odds ratio of hav-
ing a detectable viral load of 2.31 (95% confidence inter-
val (CI): 1.99–2.68) in non-adherent patients compared to
adherent patients [77]. In addition, they found that stud-
ies using a threshold for non-adherence below 95% had
stronger association with treatment failure suggesting a
lower threshold to be more appropriate. Predictive validity
for estimation recall has also been established for virologic
and immunologic outcomes [78–80].
Strategies to improve accuracy of self-report
Regardless of the evidence of the validity of self-report, it
is clear there should be a focus on improving the accur-
acy of self-report. Review of the literature has identified
several issues that need to be considered in the quest for
the best self-report tool: what questions should be asked,
what recall period should be used, and how the question-
naire should be administered.
Which instrument should be used?
Examples of instruments using estimation recall include
the Swiss HIV Cohort Study (SHCS) adherence question-
naire [81, 82], visual analogue scales [83, 84], and the
Case Index Questionnaire [80]. A common used example
of an instrument with count-based recall is the AIDS Clin-
ical Trial Group (ATCG) questionnaire [85]. Lu and col-
leagues found that estimation of one’s ability to adhere,
outperformed count-based measures of adherence in re-
lation to MEMS data [86]. Similarly, Schneider and col-
leagues found that patient’s found it easier to answer ques-
tions using Likert scales (in which respondents specify
their level of agreement or disagreement on a symmetric
agree-disagree scale for a series of statements), which use
estimation recall, rather than asking for the specific number
of missed doses or percentage adherence [87]. A typical
example of a 5–point Likert scale are: strongly disagree,
disagree, neither agree nor disagree, agree, strongly agree.
Recent guidelines from the EACS recommend using the
SHCS adherence questionnaire for routine clinical assess-
ment [4].
What is the optimal recall period?
Several studies suggest ways to minimise misremembering
by keeping the recall period relatively short. The optimal
recall period for count-based measures is over the last three
days [86]. Estimation recall measures have the added be-
nefit of allowing assessment over longer time frames [78]
and recent evidence suggests that a recall period of 30 days
may be optimal with less overreporting than 3–7 day recall
[75, 76, 79, 86].
How should adherence information be collected?
The way in which adherence information is collected – in-
terview with clinician, nurse or pharmacist, paper or com-
puter – will also likely have an effect on the accuracy
of the data. Intentional deception can occur both in inter-
views or with self-administered questionnaires if the re-
spondent thinksthe answers will be provided to their clini-
cian. One option is to use a self-administered questionnaire
that patients know will not be shared with their clinician.
However, interviews have the advantage that they allow
for the discussion of the reason for non-adherence and po-
tential solutions [65]. If proper training is provided, inter-
views can not only yield accurate adherence data, but con-
tribute to a positive health-care provider-patient relation-
ship, which in turn can have a positive effect on adherence
[87]. Williams and colleagues provide several strategies to
minimise social desirability bias during interviews such as
attempting to normalise non-adherence and avoiding re-
sponses to reports implying judgment (positive or negative)
[66]. Other strategies include encouraging patients to take
longer to respond or using cues to jog patients’ memory
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[75], such as asking about their regular strategies for taking
medication and recent events that might have interrupted
their normal routine.
Using adherence in clinical-decision
making
As much as adherence research has enlightened the medic-
al community as to the importance of adherence as a pre-
dictor of clinical outcomes, it still needs to go that one step
further and provide clinicians with a clear strategy for using
adherence information in routine clinical care as a method
of preventing negative clinical outcomes. Knowing who is
at risk for non-adherence and therefore a good candidate
for adherence support or interventions would be extremely
valuable information for clinicians. Critical information is
missing to allow clinicians to practice evidence-based
medicine – defined as the conscientious, explicit, and ju-
dicious use of current best evidence in making decisions
about the care of individual patients.
There are clinics with success stories – Krummenacher
and colleagues reported high retention and persistence rates
with their interdisciplinary adherence programme that sup-
ports patients at risk for non-adherence with MEMS and
motivational interviewing [88, 89]. Although this pro-
gramme as a whole is not transportable to all settings, es-
pecially those with limited resources, it still offers an im-
portant example of fostering a collaborative relationship
between patient and clinician and interdisciplinary team-
work for improved patient care.
So what gaps do researchers need to fill in order for adher-
ence to go from being a predictive concept to a preventat-
ive tool?
Improve current measurement tools
Take some of the most promising self-report instruments
in use and make changes that may improve accuracy. For
example, the SHCS adherence questionnaire consists of
2–items using estimation recall to ask about timing adher-
ence and drug holidays in the last 30 days [82]. This val-
idated instrument [78, 82] could be expanded to cover the
timing and food restriction dimensions of adherence, as
well as including a visual analogue scale. These modifica-
tions could be done working with psychologists in the field
of memory and recall to develop a better understanding of
how respondents interpret adherence questions and what
strategies they use to recall their behaviour and formulate
responses. Experts in cognitive interviewing can advise on
how best to administer the questionnaire to reduce inten-
tional deception.
Fill the evidence gap
Using selected measurement tools, researchers need to
provide ART class or even regimen-based cut-offs for
when non-adherence leads to negative clinical outcomes. It
has been shown that the majority of patients on potent re-
gimens are able to maintain viral suppression at adherence
rates lower than 95% [18–21], however, specific levels ac-
cording to class or regimen remain unknown. In addition,
the simplest regimen is not always the best one for the
patient [90]. Understanding specific forgiveness levels of
various ART regimens can help patients and clinicians de-
cide which regimen provides the best fit. Moreover, ad-
herence rates initially required to reach undetectable viral
loads, may not have the same adherence rate to maintain an
undetectable viral load over the long run [22]. Prospective
studies for specific regimens are lacking.
Develop surveillance strategies for adherence
There are many unanswered questions as how best to mon-
itor HIV patients and specifically the potential role of ad-
herence. In settings with only limited or no viral load test-
ing, adherence could be used as a proxy for viral load or as
an indicator of when viral load testing is warranted. There
is some evidence that this strategy could work as well as if
not better than CD4 monitoring [91]. There are known risk
factors for poor adherence including younger age, side ef-
fects, low self-efficacy, lack of social support, and accept-
ability of the regimen by the patient [58, 81, 92]. Monit-
oring strategies could be tailored to different risk groups
and populations (HIV-negative on PrEP versus HIV-posit-
ive on ART) as the challenges in taking daily medication in
a healthy person can differ from that of a chronically ill pa-
tient.
Develop adherence interventions and support
programmes
Once it is known what level of non-adherence should serve
as a warning for future treatment failure, clinicians need to
know what to do with these at-risk patients. Amico and col-
leagues did a review of ART adherence interventions and
found the effect to be small and varied [93]. Intervention
effects tended to be higher in studies which provided di-
dactic information on ART and included interactive discus-
sion of cognitions, motivations, and expectations regarding
adherence. Development and testing of adherence interven-
tions makes the most sense when it is clear how best to
measure adherence. Once measurement methods are stand-
ardised, promising interventions that target those with dif-
ferent levels of non-adherence to provide individual-based
support can be tested and adopted into clinical practice.
Conclusions
So, yes, asking about adherence, regardless of how one
asks, is better than flipping a coin and can even provide
strong evidence. However, it is clear that promising self-
assessment tools can be improved upon and then adopted
into routine clinical care. Then there is an urgent need to
fill the gaps in adherence research. In the era of ART as
prevention for acquiring HIV, the consequences of non-ad-
herence have taken on broader public health implications.
Clinicians need adherence measures that can be easily im-
plemented in clinical care with clear guidelines as to how
to interpret adherence responses so that evidence-based de-
cisions can be made.
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